Skip to main content
Y-Biologics, Inc logo

Y-Biologics, Inc — Investor Relations & Filings

Ticker · 338840 ISIN · KR7338840002 KO Professional, scientific and technical activities
Open in API
Filings indexed 117 across all filing types
Latest filing 2024-03-21 Audit Report / Informat…
Country KR South Korea
Listing KO 338840

About Y-Biologics, Inc

https://ybiologics.com/en/

Y-Biologics, Inc. is a biotechnology company specializing in the discovery and development of novel antibody-based therapeutics. The company's primary focus is on immuno-oncology, where it develops next-generation multispecific antibodies for the treatment of cancer. Y-Biologics leverages its proprietary human antibody discovery platform to advance its internal pipeline and support collaborations through technology transfers and joint development partnerships.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Y-Biologics. It provides the auditor's opinion (unqualified/proper), key financial data, and details regarding capital impairment and operating losses. While it contains financial data, it is a summary announcement of the audit report submission to the regulatory body (KRX), fitting the definition of a report publication announcement or a regulatory filing regarding audit results rather than the full annual report itself. FY 2023
2024-03-21 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2023 (Jan 1, 2023 - Dec 31, 2023) for Y-Biologics, Inc. It contains detailed company information, management history, capital structure, and business descriptions, which are standard components of a comprehensive annual financial report in the South Korean regulatory framework (DART). It is not an announcement of a report, but the report itself. FY 2023
2024-03-21 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Y-Biologics. It outlines the meeting agenda, including the approval of financial statements, board changes, and remuneration limits. This type of document is specifically designed to provide shareholders with the necessary information to vote at an upcoming Annual General Meeting (AGM). Therefore, it falls under the AGM Information category.
2024-03-14 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and includes a '정정신고' (Correction Report). It details the agenda items for an upcoming Annual General Meeting (AGM), such as financial statement approval, board remuneration, and stock option grants. Since this document provides the formal notice and agenda for the meeting rather than the presentation materials used during the meeting, it falls under Proxy Solicitation & Information Statement (PSI) as it informs shareholders of the meeting details and agenda items for their vote.
2024-03-08 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Y-Biologics. It outlines the date, location, and agenda items (such as financial statement approval and stock option grants) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-02-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Y-Biologics regarding a significant change in revenue or profit/loss structure (exceeding 15% for large corporations or 30% for others). This is a standard financial disclosure required by the Korea Exchange (KRX) when financial results deviate significantly from the previous period. It provides key financial highlights and reasons for the variance, which fits the definition of an Earnings Release (ER) as it is an initial announcement of financial results rather than a full annual report or a mere publication notice. FY 2023
2024-02-15 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.